BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 32283231)

  • 21. CDKN2A germ-line mutations in individuals with multiple cutaneous melanomas.
    Hashemi J; Platz A; Ueno T; Stierner U; Ringborg U; Hansson J
    Cancer Res; 2000 Dec; 60(24):6864-7. PubMed ID: 11156381
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Genotype-phenotype relationships in U.S. melanoma-prone families with CDKN2A and CDK4 mutations.
    Goldstein AM; Struewing JP; Chidambaram A; Fraser MC; Tucker MA
    J Natl Cancer Inst; 2000 Jun; 92(12):1006-10. PubMed ID: 10861313
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Analysis of Latvian familial melanoma patients shows novel variants in the noncoding regions of CDKN2A and that the CDK4 mutation R24H is a founder mutation.
    Veinalde R; Ozola A; Azarjana K; Molven A; Akslen LA; Doniņa S; Proboka G; Cēma I; Baginskis A; Pjanova D
    Melanoma Res; 2013 Jun; 23(3):221-6. PubMed ID: 23546221
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Age does not appear to be a major indicator of CDKN2A or CDK4 mutations in melanoma patients in Spain.
    Nagore E; Montoro A; Oltra S; Ledesma E; Botella-Estrada R; Millán JM; Oliver V; Fortea JM; Guillén C
    Melanoma Res; 2005 Dec; 15(6):555-8. PubMed ID: 16314743
    [No Abstract]   [Full Text] [Related]  

  • 25. Genetic counselling and high-penetrance susceptibility gene analysis reveal the novel CDKN2A p.D84V (c.251A>T) mutation in melanoma-prone families from Italy.
    Borroni RG; Manganoni AM; Grassi S; Grasso M; Diegoli M; Giorgianni C; Favalli V; Pavoni L; Cespa M; Arbustini E
    Melanoma Res; 2017 Apr; 27(2):97-103. PubMed ID: 28060055
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Population-based prevalence of CDKN2A and CDK4 mutations in patients with multiple primary melanomas.
    Helsing P; Nymoen DA; Ariansen S; Steine SJ; Maehle L; Aamdal S; Langmark F; Loeb M; Akslen LA; Molven A; Andresen PA
    Genes Chromosomes Cancer; 2008 Feb; 47(2):175-84. PubMed ID: 18023021
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High prevalence of the G101W germline mutation in the CDKN2A (P16(ink4a)) gene in 62 Italian malignant melanoma families.
    Mantelli M; Barile M; Ciotti P; Ghiorzo P; Lantieri F; Pastorino L; Catricalà C; Torre GD; Folco U; Grammatico P; Padovani L; Pasini B; Rovini D; Queirolo P; Rainero ML; Santi PL; Sertoli RM; Goldstein AM; Bianchi-Scarrà G; ;
    Am J Med Genet; 2002 Jan; 107(3):214-21. PubMed ID: 11807902
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeted germline sequencing of patients with three or more primary melanomas reveals high rate of pathogenic variants.
    Li C; Liu T; Tavtigian SV; Boucher K; Kohlmann W; Cannon-Albright L; Grossman D
    Melanoma Res; 2020 Jun; 30(3):247-251. PubMed ID: 31567591
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A flexible multiplex bead-based assay for detecting germline CDKN2A and CDK4 variants in melanoma-prone kindreds.
    Lang JM; Shennan M; Njauw JC; Luo S; Bishop JN; Harland M; Hayward NK; Tucker MA; Goldstein AM; Landi MT; Puig S; Gruis NA; Bergman W; Bianchi-Scarra G; Ghiorzo P; Hogg D; Tsao H
    J Invest Dermatol; 2011 Feb; 131(2):480-6. PubMed ID: 21085193
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CDKN2A (P16(INK4a)) and CDK4 mutation analysis in 131 Australian melanoma probands: effect of family history and multiple primary melanomas.
    Holland EA; Schmid H; Kefford RF; Mann GJ
    Genes Chromosomes Cancer; 1999 Aug; 25(4):339-48. PubMed ID: 10398427
    [TBL] [Abstract][Full Text] [Related]  

  • 31. 3'UTR-CDKN2A and CDK4 Germline Variants Are Associated With Susceptibility to Cutaneous Melanoma.
    Tovar-Parra D; Gil-Quiñones SR; Nova J; Gutiérrez-Castañeda LD
    In Vivo; 2021; 35(3):1529-1536. PubMed ID: 33910831
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prevalence of Germline BAP1, CDKN2A, and CDK4 Mutations in an Australian Population-Based Sample of Cutaneous Melanoma Cases.
    Aoude LG; Gartside M; Johansson P; Palmer JM; Symmons J; Martin NG; Montgomery GW; Hayward NK
    Twin Res Hum Genet; 2015 Apr; 18(2):126-33. PubMed ID: 25787093
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rare missense variants in POT1 predispose to familial cutaneous malignant melanoma.
    Shi J; Yang XR; Ballew B; Rotunno M; Calista D; Fargnoli MC; Ghiorzo P; Bressac-de Paillerets B; Nagore E; Avril MF; Caporaso NE; McMaster ML; Cullen M; Wang Z; Zhang X; ; ; ; Bruno W; Pastorino L; Queirolo P; Banuls-Roca J; Garcia-Casado Z; Vaysse A; Mohamdi H; Riazalhosseini Y; Foglio M; Jouenne F; Hua X; Hyland PL; Yin J; Vallabhaneni H; Chai W; Minghetti P; Pellegrini C; Ravichandran S; Eggermont A; Lathrop M; Peris K; Scarra GB; Landi G; Savage SA; Sampson JN; He J; Yeager M; Goldin LR; Demenais F; Chanock SJ; Tucker MA; Goldstein AM; Liu Y; Landi MT
    Nat Genet; 2014 May; 46(5):482-6. PubMed ID: 24686846
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prevalence of variations in melanoma susceptibility genes among Slovenian melanoma families.
    Peric B; Cerkovnik P; Novakovic S; Zgajnar J; Besic N; Hocevar M
    BMC Med Genet; 2008 Sep; 9():86. PubMed ID: 18803811
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Association of the POT1 Germline Missense Variant p.I78T With Familial Melanoma.
    Wong K; Robles-Espinoza CD; Rodriguez D; Rudat SS; Puig S; Potrony M; Wong CC; Hewinson J; Aguilera P; Puig-Butille JA; Bressac-de Paillerets B; Zattara H; van der Weyden L; Fletcher CDM; Brenn T; Arends MJ; Quesada V; Newton-Bishop JA; Lopez-Otin C; Bishop DT; Harms PW; Johnson TM; Durham AB; Lombard DB; Adams DJ
    JAMA Dermatol; 2019 May; 155(5):604-609. PubMed ID: 30586141
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CDKN2A and BAP1 germline mutations predispose to melanoma and mesothelioma.
    Betti M; Aspesi A; Biasi A; Casalone E; Ferrante D; Ogliara P; Gironi LC; Giorgione R; Farinelli P; Grosso F; Libener R; Rosato S; Turchetti D; Maffè A; Casadio C; Ascoli V; Dianzani C; Colombo E; Piccolini E; Pavesi M; Miccoli S; Mirabelli D; Bracco C; Righi L; Boldorini R; Papotti M; Matullo G; Magnani C; Pasini B; Dianzani I
    Cancer Lett; 2016 Aug; 378(2):120-30. PubMed ID: 27181379
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Loss of p16 expression and copy number changes of CDKN2A in a spectrum of spitzoid melanocytic lesions.
    Harms PW; Hocker TL; Zhao L; Chan MP; Andea AA; Wang M; Harms KL; Wang ML; Carskadon S; Palanisamy N; Fullen DR
    Hum Pathol; 2016 Dec; 58():152-160. PubMed ID: 27569296
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CDKN2A germline mutations are not associated with poor survival in an Italian cohort of melanoma patients.
    Dalmasso B; Pastorino L; Ciccarese G; Andreotti V; Grillo F; Mastracci L; Spagnolo F; Ballestrero A; Queirolo P; Bruno W; Ghiorzo P
    J Am Acad Dermatol; 2019 May; 80(5):1263-1271. PubMed ID: 30274933
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CDKN2A/CDK4 molecular study on 155 Italian subjects with familial and/or primary multiple melanoma.
    Majore S; De Simone P; Crisi A; Eibenschutz L; Binni F; Antigoni I; De Bernardo C; Catricalà C; Grammatico P
    Pigment Cell Melanoma Res; 2008 Apr; 21(2):209-11. PubMed ID: 18363633
    [No Abstract]   [Full Text] [Related]  

  • 40. CDKN2A mutations and MC1R variants in Italian patients with single or multiple primary melanoma.
    Pastorino L; Bonelli L; Ghiorzo P; Queirolo P; Battistuzzi L; Balleari E; Nasti S; Gargiulo S; Gliori S; Savoia P; Abate Osella S; Bernengo MG; Bianchi Scarrà G
    Pigment Cell Melanoma Res; 2008 Dec; 21(6):700-9. PubMed ID: 18983535
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.